AstraZeneca UK Limited

Commercial

Samuel Adamsson Eryd - Chief Investigator - AstraZeneca AB (Sweden)Ellen Berni - Corresponding Applicant - Pharmatelligence LimitedCraig Currie - Collaborator - Pharmatelligence LimitedHungta Chen - Collaborator - Astra Zeneca Inc - USAKarolina Andersson Sundell - Collaborator - Astra Zeneca R&D Molndal SwedenPhilip Ambery - Collaborator - Astra Zeneca Ltd - UK HeadquartersPhillip Hunt - Collaborator - Astra Zeneca Inc - USASara Jenkins-Jones - Collaborator - Pharmatelligence Limited

CPRD477

Corticosteroids (CS) are common treatments for managing diseases that cause inflammation, such as arthritis; however, they also have side-effects on sugar metabolism and on bones. Even though they are used commonly, we don’t really have a clear understanding about the association of use of these drugs with the risk of developing either diabetes (DM) or osteoporosis.

Systemic corticosteroids (CS) are important for managing inflammation, but have profound endocrine effects on glucose metabolism and bone turnover. Few consistent data exist describing the association of CS and risks of developing either diabetes mellitus (DM) or osteoporosis, and progression of DM.

24/03/2021

Release